12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Company News  |  Deals

ActoGeniX, Merck deal

ActoGeniX said it partnered with Merck to develop and validate an antibody therapy for an undisclosed indication using ActoGeniX's...

Read the full 73 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >